Fig. 1 · Structure

Documents & Downloads

Iopromide

Cat. No. A11878 CAS 73334-07-3
Iopromide is a nonionic, injectable radio-contrast medium.

In Stock

Publications for Iopromide

2 publications citing this product

  1. Jingyeong Shin, .et al. , Chemical Engineering Journal, 2023, December
  2. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In HEK 293 cells, Ultravist-formulated iopromide at 50 mgI/ml for 24 h increased CM-H2DCFDA fluorescence versus untreated cells, supporting an oxidative-stress-associated response. This experiment does not establish a specific molecular target or the mechanism of radiographic contrast enhancement. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Iopromide Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Iopromide from 2 published references. In vivo models include adult Sprague Dawley rats, males and females, 225±15 g.

Iopromide In Vitro Studies

Ultravist-formulated iopromide reduced HEK 293 MTT viability in concentration- and time-dependent experiments. Reported IC50 values were 187±3.45 mgI/ml at 24 h and 53.10±1.87 mgI/ml at 48 h; the definition of these uncertainties is unclear. These are cell-assay endpoints expressed as iodine concentration. [1]

Iopromide reduces HEK 293 MTT viability

Cell-based study · HEK 293 human embryonic kidney cell line; DMEM with 10% fetal bovine serum [1]

MTT signal declined with increasing concentration and longer exposure relative to untreated cells. Reported IC50 values are assay endpoints, not treatment doses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT viability relative to untreated controlReported IC50 24 h: 187±3.45 mgI/ml; 48 h: 53.10±1.87 mgI/ml[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 25, 50, 100 and 200 mgI/ml
Exposure duration
24 or 48 h
Method
Ultravist exposure followed by MTT assay; untreated control normalized to 100%
Reported limits
Ultravist stock concentration and excipient-matched/osmolality-matched control are not described. IC50 fitting and the uncertainty definition for the reported IC50 values are not specified.
Methods and source locations

Compound reported in the paper: Iopromide; Compound label in the paper: Ultravist commercial iopromide formulation

High-concentration cell-culture effects of the tested formulation; no inference of human dosing or Adooq lot performance.

Methods: Reagents and chemicals; Morphology and cell viability; Statistical analysis. Results first paragraph and Figure 1A–B.

MTT viability relative to untreated control: MTT absorbance at 570 nm; Figure 1 caption: mean±SE, n=3; general statistics section: at least three independent experiments, mean±SD. IC50 ± definition unresolved. — Results: Iopromide significantly inhibited HEK 293 cell proliferation; Figure 1A–B and caption; Methods: Statistical analysis.

Iopromide increases an oxidative-stress probe signal in HEK 293 cells

Cell-based study · HEK 293 cells; untreated cells as comparator [1]

Iopromide increased CM-H2DCFDA fluorescence. This supports an oxidative-stress-associated cellular response without proving a specific ROS species or a causal ROS-to-AKT pathway.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CM-H2DCFDA fluorescence compared with untreated cellsDirection Increased[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 mgI/ml
Exposure duration
24 h
Method
Ultravist exposure; CM-H2DCFDA fluorescence measured with an image cytometer
Reported limits
An excipient/osmolality-matched comparator is not described. The NAC rescue experiment is not adopted because its dosing and exposure timing are insufficiently specified.
Methods and source locations

Compound reported in the paper: Iopromide; Compound label in the paper: Ultravist commercial iopromide formulation

Qualitative oxidative-response evidence under the reported cell-culture conditions.

Methods: Detection of reactive oxygen species production; Reagents and chemicals; Results: Iopromide elicited ROS production; Figure 9A–B and caption.

CM-H2DCFDA fluorescence compared with untreated cells: 50 μM CM-H2DCFDA; 30 min staining at 37°C; Figure 9 caption reports mean±SE, n=3, ***p<0.001. — Methods: Detection of reactive oxygen species production; Figure 9A–B and caption.

Iopromide In Vivo Studies

In rats pretreated with indomethacin and L-NAME, iopromide challenge increased serum creatinine, BUN, tubular injury and TUNEL positivity at 24 h. rhMG53 pretreatment attenuated these changes, while rhMG53 alone did not affect creatinine or BUN. The findings apply to this sensitized model and do not establish clinical protection. [2]

Sensitized rat kidney-injury model and rhMG53 pretreatment

Animal study · Adult Sprague Dawley rats, males and females, 225±15 g [2]

In a sensitized model, iopromide challenge increased renal-function injury markers, tubular damage and TUNEL positivity. rhMG53 pretreatment attenuated these changes; rhMG53 alone did not change SCr or BUN.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum creatinine and blood urea nitrogenDirection and significance Increased in CI-AKI vs control; reduced with rhMG53 pretreatment; rhMG53 alone had no effect[2]
Tubular injury score and TUNEL-positive cellsDirection and significance Increased after CI-AKI; attenuated by rhMG53 pretreatment[2]

Conditions shared by the study groups

Route
Intravenous administration through jugular cannulation
Frequency
Single experimental challenge
Treatment course
Outcomes assessed 24 h after iopromide
Vehicle
Indomethacin dissolved in DMSO; L-NAME dissolved in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Control
Saline instead of iopromide; comparator protocol described in CI-AKI model
Reference groupLower injury endpoints than CI-AKI[2]
CI-AKI challenge
Indomethacin 10 mg/kg; L-NAME 10 mg/kg; iopromide 1600 mg I/kg
Saline substituted for iopromideIncreased SCr, BUN, pathological damage score and TUNEL positivity[2]
rhMG53 pretreatment plus CI-AKI
rhMG53 2 mg/kg before the same sensitized challenge
CI-AKI group without rhMG53Attenuated renal-function, histological and TUNEL changes[2]
rhMG53 comparator
rhMG53 2 mg/kg in control animals
Control animals without rhMG53No impact on SCr or BUN[2]
Control
Model: Adult Sprague Dawley rats, both sexes, 225±15 g
Reported limits: Iopromide supplier, commercial formulation and excipients are not identified in the acquired methods. Sex-specific outcomes are not reported.
CI-AKI challenge
Model: Adult Sprague Dawley rats, both sexes, 225±15 g
Reported limits: Iopromide supplier, commercial formulation and excipients are not identified in the acquired methods. Sex-specific outcomes are not reported.
rhMG53 pretreatment plus CI-AKI
Model: Adult Sprague Dawley rats, both sexes, 225±15 g
Reported limits: Iopromide supplier, commercial formulation and excipients are not identified in the acquired methods. Sex-specific outcomes are not reported.
rhMG53 comparator
Model: Adult Sprague Dawley rats, both sexes, 225±15 g
Reported limits: Iopromide supplier, commercial formulation and excipients are not identified in the acquired methods. Sex-specific outcomes are not reported.
Methods and source locations

Compound reported in the paper: Iopromide; Compound label in the paper: Iopromide described as low-osmolality nonionic iodinated contrast medium

Model-specific injury and combination pretreatment findings; not proof of clinical benefit or effects of iopromide alone in unsensitized animals.

Methods: Animals; CI-AKI model; Renal function; Renal histopathology; TUNEL; Statistical analysis. Results: CI-AKI was ameliorated; Figure 2A–F.

Serum creatinine and blood urea nitrogen: Automated analyzer; mean±SEM; n=8; Figure 2A–B: P<0.05 vs control and vs CI-AKI as marked. — Methods: Renal function and Statistical analysis; Figure 2A–B and caption.

Tubular injury score and TUNEL-positive cells: Blinded H&E injury scoring, 0–5; n=8. TUNEL n=4. Mean±SEM; P<0.05 comparisons marked in Figure 2. — Methods: Renal histopathology and TUNEL assay; Figure 2C–F and caption.

Control · Methods: CI-AKI model; Figure 2A–F and caption.

CI-AKI challenge · Methods: CI-AKI model; Figure 2A–F and caption.

rhMG53 pretreatment plus CI-AKI · Methods: CI-AKI model; Figure 2A–F and caption.

rhMG53 comparator · Methods: CI-AKI model; Figure 2A–F and caption.

Specifications

Manufacturer Adooq Bioscience
CAS Number 73334-07-3
Formula C18H24I3N3O8
Molecular Weight 791.12
SMILES
CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (115.02 mM)
Water 91 mg/mL (115.02 mM)
Ethanol 91 mg/mL (115.02 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Iopromide Research References

  1. [1] Tsai YF, Yang JS, Tsai FJ, et al. High Concentration of Iopromide Induces Apoptosis and Autophagy in Human Embryonic Kidney Cells via Activating a ROS-dependent Cellular Stress Pathway In vivo (Athens, Greece) (2021). PMID: 34697153 DOI: 10.21873/invivo.12617 Source material
  2. [2] Liu C, Hu YH, Han Y, et al. MG53 protects against contrast-induced acute kidney injury by reducing cell membrane damage and apoptosis Acta pharmacologica Sinica (2020). PMID: 32424239 DOI: 10.1038/s41401-020-0420-8 Source material

Publications

2 publications citing this product

  1. Jingyeong Shin, .et al. , Chemical Engineering Journal, 2023, December
  2. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489

Added to your cart

View Cart Checkout
Loading...